Guo Ying, Ge Xu, Wang Wei, Wang Rongrong, Chen Qianmin, Wang Hong
Department of stomatology, General Hospital of Shenzhen University, Shenzhen, China.
Dental Department, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Medicine (Baltimore). 2024 Dec 13;103(50):e40837. doi: 10.1097/MD.0000000000040837.
Osteoporosis and periodontitis, prevalent in middle-aged and elderly populations, share common features of bone loss and chronic inflammation. This study explores the hypothesis that Epimedium, known for its bone-strengthening properties, may enhance the effectiveness of conventional osteoporosis treatment in patients with coexisting periodontitis. This retrospective study analyzed clinical data from 120 patients with osteoporosis and periodontitis, divided into 2 groups. The control group received calcium carbonate, vitamin D, and zoledronic acid (CC + VD + ZA) therapy, while the observation group received additional Epimedium flavonoid treatment. Outcomes assessed included changes in bone mineral density (BMD), bone metabolism markers (β-CTx, N-MID, CT, ALP), periodontal indices (PD, AL, SBI, PLI), and inflammatory markers in gingival crevicular fluid (GCF) before and 6 months posttreatment. Compared to the control group, the observation group showed significantly greater increases in lumbar spine and proximal femur BMD and reductions in BM markers (P < .05). Periodontal health metrics (PD, AL, SBI, PLI) and GCF inflammatory markers (TNF-α, IL-1β, IL-6, IL-8, hs-CRP, ICAM-1, HMGB1, PGE2) were markedly improved in the observation group, correlating with enhanced total effective rates (TER) for osteoporosis (95.0%) and periodontitis (91.7%) and a reduced adverse event rate (AER). Epimedium shows promise as an adjunctive therapy in patients with osteoporosis and periodontitis, contributing to improved BMD, reduced inflammation, and enhanced periodontal health, suggesting its potential for broader clinical application in managing these coexisting conditions.
骨质疏松症和牙周炎在中老年人群中普遍存在，具有骨质流失和慢性炎症的共同特征。本研究探讨了以下假说：淫羊藿以其增强骨骼的特性而闻名，可能会提高传统骨质疏松症治疗对同时患有牙周炎患者的疗效。这项回顾性研究分析了120例骨质疏松症和牙周炎患者的临床资料，将其分为两组。对照组接受碳酸钙、维生素D和唑来膦酸（CC + VD + ZA）治疗，而观察组则额外接受淫羊藿黄酮治疗。评估的结果包括治疗前和治疗后6个月骨密度（BMD）、骨代谢标志物（β-CTx、N-MID、CT、ALP）、牙周指数（PD、AL、SBI、PLI）以及龈沟液（GCF）中炎症标志物的变化。与对照组相比，观察组腰椎和股骨近端BMD的增加幅度明显更大，骨代谢标志物减少（P < 0.05）。观察组的牙周健康指标（PD、AL、SBI、PLI）和GCF炎症标志物（TNF-α、IL-1β、IL-6、IL-8、hs-CRP、ICAM-1、HMGB1、PGE2）明显改善，与骨质疏松症（95.0%）和牙周炎（91.7%）的总有效率提高以及不良事件发生率降低相关。淫羊藿有望作为骨质疏松症和牙周炎患者的辅助治疗方法，有助于改善骨密度、减轻炎症并增强牙周健康，表明其在管理这些并存疾病方面具有更广泛临床应用的潜力。
